There is a rare genetic disease in which people do not have functioning SGLT2.
FORBES: Another Blow For Diabetes Pills
By inhibiting SGLT2, the drugs cause a substantial increase in the amount of glucose that flows out in the urine.
The companies will join forces to develop and commercialize ertugliflozin (PF-04971729), an oral sodium glucose cotransporter (SGLT2) inhibitor for type 2 diabetes which is about to begin phase 3 studies.
FORBES: What The Pfizer-Merck Diabetes Deal Teaches About Today's Pharma R&D
应用推荐
模块上移
模块下移
不移动